These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 6064688)

  • 1. Factors affecting plasma clot absorbance and fibrin mass.
    Rosenfeld L
    Clin Chim Acta; 1967 Oct; 18(1):1-10. PubMed ID: 6064688
    [No Abstract]   [Full Text] [Related]  

  • 2. Clot opacity and the thrombin-plasma reaction.
    Rosenfeld L
    Arch Biochem Biophys; 1965 Sep; 111(3):660-70. PubMed ID: 5862214
    [No Abstract]   [Full Text] [Related]  

  • 3. Equilibria in the fibrinogen--fibrin conversion. 8. Polymerization of acceptor-modified fibrin monomer.
    Endres GF; Scheraga HA
    Biochemistry; 1968 Dec; 7(12):4219-26. PubMed ID: 5750166
    [No Abstract]   [Full Text] [Related]  

  • 4. Rheology of fibrin clots. II. Linear viscoelastic behavior in shear creep.
    Gerth C; Roberts WW; Ferry JD
    Biophys Chem; 1974 Oct; 2(3):208-17. PubMed ID: 4474029
    [No Abstract]   [Full Text] [Related]  

  • 5. CHEMISTRY AND PHYSIOLOGY OF THE FIBRINOGEN-FIBRIN TRANSITION.
    LAKI K; GLADNER JA
    Physiol Rev; 1964 Apr; 44():127-60. PubMed ID: 14152903
    [No Abstract]   [Full Text] [Related]  

  • 6. Acceleration of fibrin polymerization by dextran and ficoll. Interaction with calcium and plasma proteins.
    Abildgaard U
    Scand J Clin Lab Invest; 1966; 18(5):518-24. PubMed ID: 5964454
    [No Abstract]   [Full Text] [Related]  

  • 7. THE BINDING OF HUMAN FIBRINOGEN TO NATIVE AND FRACTION FIBRINS AND THE INHIBITION OF POLYMERIZATION OF A NEW HUMAN FIBRIN MONOMER BY FIBRINOGEN.
    COPLEY AL; LUCHINI BW
    Life Sci (1962); 1964 Nov; 3():1293-305. PubMed ID: 14231779
    [No Abstract]   [Full Text] [Related]  

  • 8. Exposure of fibrinogen and thrombin to nitric oxide donor ProliNONOate affects fibrin clot properties.
    Helms CC; Kapadia S; Gilmore AC; Lu Z; Basu S; Kim-Shapiro DB
    Blood Coagul Fibrinolysis; 2017 Jul; 28(5):356-364. PubMed ID: 27755019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular aspects of fibrin clot solubilization.
    Gaffney PJ
    Nat New Biol; 1971 Dec; 234(52):281-2. PubMed ID: 4257271
    [No Abstract]   [Full Text] [Related]  

  • 10. Inactivation of "Arvin" by plasma proteins.
    Pitney WR; Regoeczi E
    Br J Haematol; 1970 Jul; 19(1):67-81. PubMed ID: 4195300
    [No Abstract]   [Full Text] [Related]  

  • 11. Additive roles of platelets and fibrinogen in whole-blood fibrin clot formation upon dilution as assessed by thromboelastometry.
    Ninivaggi M; Feijge MA; Baaten CC; Kuiper GJ; Marcus MA; Ten Cate H; Lancé MD; Heemskerk JW; van der Meijden PE
    Thromb Haemost; 2014 Mar; 111(3):447-57. PubMed ID: 24258426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SOLUBILITY OF FIBRIN CLOTS IN SOLUTIONS OF HEPARIN.
    TRIANTAPHYLLOPOULOS DC; TRIANTAPHYLLOPOULOS E
    Nature; 1964 Dec; 204():1096-8. PubMed ID: 14243392
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of sodium bicarbonate on in vitro conversion of fibrinogen to fibrin.
    Wong DW
    J Pharm Sci; 1980 Aug; 69(8):978-80. PubMed ID: 7400952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coupling of fibrin with low density lipoproteins.
    Skrzydlewski Z
    Acta Med Acad Sci Hung; 1976; 33(2):171-7. PubMed ID: 199019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Binding of carboxypeptidase N to fibrinogen and fibrin.
    Talens S; Lebbink JH; Malfliet JJ; Demmers JA; Uitte de Willige S; Leebeek FW; Rijken DC
    Biochem Biophys Res Commun; 2012 Oct; 427(2):421-5. PubMed ID: 23000409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies on the thrombin clotting time. II. The influence of fibrin degradation products.
    Arnesen H
    Scand J Haematol; 1973; 10(4):291-7. PubMed ID: 4764611
    [No Abstract]   [Full Text] [Related]  

  • 17. Fibrin clot structure - pro-fibrinolytic effect of oral contraceptives in apparently healthy women.
    Sidelmann JJ; Kluft C; Krug AH; Winkler U; Jespersen J; Gram JB
    Thromb Haemost; 2017 Apr; 117(4):700-705. PubMed ID: 28150855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unfavorably Altered Fibrin Clot Properties in Patients with Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome): Association with Thrombin Generation and Eosinophilia.
    Mastalerz L; Celińska-Lӧwenhoff M; Krawiec P; Batko B; Tłustochowicz W; Undas A
    PLoS One; 2015; 10(11):e0142167. PubMed ID: 26540111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coarse-grained molecular dynamics simulations of fibrin polymerization: effects of thrombin concentration on fibrin clot structure.
    Yesudasan S; Wang X; Averett RD
    J Mol Model; 2018 Apr; 24(5):109. PubMed ID: 29623504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamics of clot growth induced by thrombin diffusing into nonstirred citrate human plasma.
    Sinauridze EI; Volkova RI; Krasotkina YV; Sarbash VI; Ataullakhanov FI
    Biochim Biophys Acta; 1998 Nov; 1425(3):607-16. PubMed ID: 9838224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.